Jazz Pharma(JAZZ.US)

Event Tracking

Jan6

Needham Maintains Jazz Pharmaceuticals Buy Rating With $210 Price Target

19:17

Jazz Pharmaceuticals Announces Positive Results of Ziihera Phase III Clinical Trial for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma

18:33

Dec17

Jazz Pharma to Hold Investor Webcast on Zanidatamab Phase 3 Trial Results

21:15

Dec14

Jazz Pharmaceuticals Reports Positive Clinical Updates for Epidiolex and Ziihera

23:43

Dec9

Jazz Pharmaceuticals' VP and CAO Patricia Carr Sells Shares

22:32

Jazz Pharmaceuticals' Senior Vice President Disposes of Common Stock

22:26

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 1.126 B, Net Income 251.41 M, EPS 4.08

Aug5

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.046 B, Net Income -718.47 M, EPS -11.7408

May6

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 897.84 M, Net Income -92.54 M, EPS -1.5175

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change